Shionogi Study for COVID-19
This study, called the ACTIV-2d (SCORPIO-HR) study, is a global Phase 3 multicenter study evaluating the safety and efficacy of the COVID-19-antiviral agent S-217622 to reduce the duration of COVID-19 symptoms. The study drug is a 3CL protease inhibitor as a once-daily oral treatment for low-risk, non-hospitalized adults with COVID-19 within five days of symptom onset.
If you join this study, you will be compensated $100 per visit (6 in-person visits required), have access to travel reimbursement and/or coordination, and receive either oral study drug or placebo. The study lasts 24 weeks and participating patients will be asked to record symptoms for 29 days in an electronic diary.